Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. The Company provides insights and accelerates to improve health and improve lives through its unparalleled diagnostics and drug development capabilities. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļLH
āļāļ·āđāļāļāļĢāļīāļĐāļąāļLabcorp Holdings Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļApr 24, 1991
āļāļĩāļāļĩāđāļSchechter (Adam H)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ70000
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļApr 24
āļāļĩāđāļāļĒāļđāđ358 S Main St
āđāļĄāļ·āļāļBURLINGTON
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX NASDAQ Basic NYSE
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ27215
āđāļāļĢāļĻāļąāļāļāđ13362291127
āđāļ§āđāļāđāļāļāđhttps://www.labcorp.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļLH
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļApr 24, 1991
āļāļĩāļāļĩāđāļSchechter (Adam H)
Mr. Adam H. Schechter
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
Dr. Brian J. Caveney, M.D., J.D.
Dr. Brian J. Caveney, M.D., J.D.
Executive Vice President, President, Early Development Research Laboratories, Chief Medical and Scientific Officer
Executive Vice President, President, Early Development Research Laboratories, Chief Medical and Scientific Officer
Mr. Lance V. Berberian
Executive Vice President - Special Advisor, Strategy
Executive Vice President - Special Advisor, Strategy
Mr. Peter M. Neupert
Independent Director
Dr. Garheng Kong, M.D., Ph.D.
Dr. Garheng Kong, M.D., Ph.D.
Lead Independent Director
Lead Independent Director
Ms. Kerrii B. Anderson, CPA
Ms. Kerrii B. Anderson, CPA
Independent Director
Ms. Amy B. Summy
Executive Vice President, Chief Marketing Officer
Executive Vice President, Chief Marketing Officer
Mr. Mark S. Schroeder
Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer
Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer
Mr. Akinbolade Oyegunwa
Executive Vice President and Chief Information and Technology Officer
Executive Vice President and Chief Information and Technology Officer
Ms. Megan D. Bailey
Executive Vice President and President - Central Laboratories and International
Executive Vice President and President - Central Laboratories and International
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. Adam H. Schechter
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
Dr. Brian J. Caveney, M.D., J.D.
Dr. Brian J. Caveney, M.D., J.D.
Executive Vice President, President, Early Development Research Laboratories, Chief Medical and Scientific Officer
Executive Vice President, President, Early Development Research Laboratories, Chief Medical and Scientific Officer
Mr. Lance V. Berberian
Executive Vice President - Special Advisor, Strategy
Executive Vice President - Special Advisor, Strategy
Mr. Peter M. Neupert
Independent Director
Dr. Garheng Kong, M.D., Ph.D.
Dr. Garheng Kong, M.D., Ph.D.
Lead Independent Director
Lead Independent Director
Ms. Kerrii B. Anderson, CPA
Ms. Kerrii B. Anderson, CPA
Independent Director
iShares U.S. Healthcare Providers ETF
Knowledge Leaders Developed World ETF
Thrivent Small-Mid Cap ESG ETF
State Street SPDR S&P Health Care Services ETF
Schwab Ariel Opportunities ETF
Invesco S&P 500 Equal Weight Health Care ETF
Nuveen ESG Mid-Cap Value ETF
Franklin Genomic Advancements ETF
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
iShares U.S. Healthcare Providers ETF
āļŠāļąāļāļŠāđāļ§āļ3.32%
Knowledge Leaders Developed World ETF
āļŠāļąāļāļŠāđāļ§āļ2.73%
Thrivent Small-Mid Cap ESG ETF
āļŠāļąāļāļŠāđāļ§āļ2.26%
State Street SPDR S&P Health Care Services ETF
āļŠāļąāļāļŠāđāļ§āļ1.9%
Schwab Ariel Opportunities ETF
āļŠāļąāļāļŠāđāļ§āļ1.62%
Brandes US Value ETF
āļŠāļąāļāļŠāđāļ§āļ1.56%
Invesco S&P 500 Equal Weight Health Care ETF
āļŠāļąāļāļŠāđāļ§āļ1.52%
Madison Covered Call ETF
āļŠāļąāļāļŠāđāļ§āļ1.49%
Nuveen ESG Mid-Cap Value ETF
āļŠāļąāļāļŠāđāļ§āļ1.4%
Franklin Genomic Advancements ETF
āļŠāļąāļāļŠāđāļ§āļ1.25%
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
692.30M
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Dec 11, 2025 going ex on Nov 26, 2025
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Sep 11, 2025 going ex on Aug 28, 2025
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Jun 11, 2025 going ex on May 29, 2025
LH.NB Final Cash Dividend of gross USD 0.72 paid on Mar 12, 2025 going ex on Feb 27, 2025
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Dec 13, 2024 going ex on Nov 26, 2024
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Sep 13, 2024 going ex on Aug 29, 2024
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Jun 12, 2024 going ex on May 24, 2024
LH.NB Final Cash Dividend of gross USD 0.72 paid on Mar 13, 2024 going ex on Feb 26, 2024
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Dec 12, 2023 going ex on Nov 07, 2023
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Sep 08, 2023 going ex on Aug 07, 2023
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ